结论
Germline testing should be considered for all patients with a new diagnosis of pancreatic cancer, regardless of family history
- Identification of germline BRCA mutation should prompt consideration of platinum-based therapy for patients with metastatic disease, followed by maintenance with a PARP inhibitor (olaparib) for those exhibiting good disease control
Somatic (tumor) testing should be considered for patients as well, with occasional mutations/genetic alterations informing treatment options (eg, immune checkpoint inhibitors) or identifying patients for appropriate clinical trials
